Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 1/20 | 0.48 |
| ▸ | TMEM97 | Q5BJF2 | 3/20 | 0.48 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.48 |
| ▸ | PSEN1 | P49768 | 1/20 | 0.43 |
| ▸ | PSEN2 | P49810 | 1/20 | 0.43 |
| ▸ | APH1B | Q8WW43 | 1/20 | 0.43 |
| ▸ | NCSTN | Q92542 | 1/20 | 0.43 |
| ▸ | APH1A | Q96BI3 | 1/20 | 0.43 |
| ▸ | PSENEN | Q9NZ42 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | NPC1 | O15118 | 2/20 | 0.43 |
| ▸ | RAB9A | P51151 | 2/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20449106 | 1.00 | PARP1 (0.48) | PARP1TMEM97SIGMAR1PSEN1PSEN2 | |
| SCHEMBL3155289 | 0.92 | PARP1 (0.53) | PARP1TMEM97SIGMAR1PSEN1PSEN2 | |
| SCHEMBL20449099 | 0.92 | PARP1 (0.53) | PARP1TMEM97SIGMAR1PSEN1PSEN2 | |
| SCHEMBL3068759 | 0.90 | PARP1 (0.48) | PARP1TMEM97SIGMAR1PSEN1PSEN2 | |
| SCHEMBL20449353 | 0.89 | TMEM97 (0.48) | PARP1TMEM97SIGMAR1KMT2ANPC1 | |
| SCHEMBL3056493 | 0.89 | TMEM97 (0.50) | PARP1TMEM97SIGMAR1KMT2A | |
| SCHEMBL20449120 | 0.89 | TMEM97 (0.48) | PARP1TMEM97SIGMAR1KMT2ANPC1 | |
| SCHEMBL2708064 | 0.88 | PARP1 (0.46) | PARP1TMEM97SIGMAR1PSEN1PSEN2 | |
| SCHEMBL20703649 | 0.88 | SIGMAR1 (0.50) | PARP1TMEM97SIGMAR1PTGDR2 | |
| SCHEMBL3066321 | 0.88 | SIGMAR1 (0.50) | PARP1TMEM97SIGMAR1PTGDR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 55 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250136612-A1 | 4',5'-DIHYDROSPIRO[PIPERIDINE-4,7'-THIENO[2,3-C]PYRAN] DERIVATIVES AS INHIBITORS OF APOL1 AND METHODS OF USING SAME | VERTEX PHARMACEUTICALS INCORPORATED | 2025-05-01 | — | — | US | disclosed |
| EP-4476228-A1 | 4',5'-DIHYDROSPIRO[PIPERIDINE-4,7'-THIENO[2,3-C]PYRAN] DERIVATIVES AS INHIBITORS OF APOL1 AND METHODS OF USING SAME | Vertex Pharmaceuticals Incorporated (US) | 2024-12-18 | — | — | EP | disclosed |
| CN-119013281-A | 4',5' -Dihydrospiro [ piperidine-4, 7' -thieno [2,3-C ] pyran ] derivatives as APOL1 inhibitors and methods of use thereof | 弗特克斯药品有限公司 | 2024-11-22 | — | — | CN | disclosed |
| WO-2023154309-A1 | 4',5'-DIHYDROSPIRO[PIPERIDINE-4,7'-THIENO[2,3-C]PYRAN] DERIVATIVES AS INHIBITORS OF APOL1 AND METHODS OF USING SAME | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2023-08-17 | — | — | WO | disclosed |
| WO-2023154309-A1 | 4',5'-DIHYDROSPIRO[PIPERIDINE-4,7'-THIENO[2,3-C]PYRAN] DERIVATIVES AS INHIBITORS OF APOL1 AND METHODS OF USING SAME | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2023-08-17 | — | — | WO | disclosed |
| CN-108290881-B | Therapeutic compounds and methods of use thereof | 健泰科生物技术公司 | 2021-12-07 | — | — | CN | disclosed |
| EP-3601273-B1 | 4-PIPERIDIN-N-(PYRIMIDIN-4-YL)CHROMAN-7-SULFONAMIDE DERIVATIVES AS SODIUM CHANNEL INHIBITORS | GENENTECH INC (US) | 2021-12-01 | — | — | EP | disclosed |
| US-20210171516-A1 | THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2021-06-10 | — | — | US | disclosed |
| US-20210107895-A1 | THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2021-04-15 | — | — | US | disclosed |
| US-10793550-B2 | 4-piperidin-n-(pyrimidin-4-yl)chroman-7-sulfonamide derivatives as sodium channel inhibitors | GENENTECH, INC. (US) | 2020-10-06 | — | — | US | disclosed |
| EP-1752449-A1 | Pharmaceutical coposition | GLAXO GROUP LIMITED (GB) | 2007-02-14 | — | — | EP | disclosed |
| US-7119092-B2 | Chemical compounds | SMITHKLINE BEECHAM CORPORATION (US) | 2006-10-10 | — | — | US | disclosed |
| US-20060142302-A1 | Chemical compounds | GLAXO GROUP LIMITED (GB) | 2006-06-29 | — | — | US | disclosed |
| US-7060702-B2 | Chemical compounds | SMITHKLINE BEECHAM CORPORATION (US) | 2006-06-13 | — | — | US | disclosed |
| EP-1377558-B1 | [1,4]-DIAZEPANE-1-CARBOXYLIC ACID DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS TACHYKININ ANTAGONISTS | GLAXO GROUP LTD (GB) | 2005-08-17 | — | — | EP | disclosed |
| US-20050137208-A1 | Chemical compounds | GLAXO GROUP LIMITED (GB) | 2005-06-23 | — | — | US | disclosed |
| EP-1524266-A1 | Pharmaceutical composition | GLAXO GROUP LIMITED (GB) | 2005-04-20 | — | — | EP | disclosed |
| EP-1326832-B1 | CHEMICAL COMPOUNDS | GLAXO GROUP LTD (GB) | 2004-10-06 | — | — | EP | disclosed |
| US-20040127485-A1 | 1,4! - diazepane -1- carboxylic acid derivatives process for their preparation and their use as tachykinin antagonists | GLAXO GROUP LIMITED (GB) | 2004-07-01 | — | — | US | disclosed |
| US-20040014770-A1 | Chemical compounds | GLAXO GROUP LIMITED (GB) | 2004-01-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10793550-B2 | 4-piperidin-n-(pyrimidin-4-yl)chroman-7-sulfonamide derivatives as sodium channel inhibitors | HCN4, SCN7A, SCN4A | PARP1 4345/4885TMEM97 1369/4885SIGMAR1 2221/4885 |
| US-20050137208-A1 | Chemical compounds | TACR2, TAC3, MC2R | PARP1 3979/4885TMEM97 2346/4885SIGMAR1 328/4885 |
| US-20210107895-A1 | THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF | KCNN3, HCN4, KCNN2 | PARP1 4206/4885TMEM97 940/4885SIGMAR1 1067/4885 |
| US-20040127485-A1 | 1,4! - diazepane -1- carboxylic acid derivatives process for their preparation and their use as tachykinin antagonists | NPY1R, CRHR1, GRIN1 | PARP1 4091/4885TMEM97 927/4885SIGMAR1 136/4885 |
| US-20250136612-A1 | 4',5'-DIHYDROSPIRO[PIPERIDINE-4,7'-THIENO[2,3-C]PYRAN] DERIVATIVES AS INHIBITORS OF APOL1 AND METHODS OF USING SAME | APOL1, PDXK, PNLIP | PARP1 3733/4885TMEM97 1006/4885SIGMAR1 793/4885 |
| US-20040014770-A1 | Chemical compounds | HCK, KCNK4, GRK4 | PARP1 3214/4885TMEM97 2557/4885SIGMAR1 434/4885 |
| US-20060142302-A1 | Chemical compounds | TACR2, TAC3, MC2R | PARP1 3979/4885TMEM97 2346/4885SIGMAR1 328/4885 |
| US-20210171516-A1 | THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF | AVPR1B, C3AR1, RHEB | PARP1 1568/4885TMEM97 3436/4885SIGMAR1 1061/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.